Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 13Recruiting 6Unknown 4Active not recruiting 4Not yet recruiting 3Terminated 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 989Neoplasms 848Carcinoma, Non-Small-Cell Lung 842Prostatic Neoplasms 527Neoplasm Metastasis 500Leukemia, Myeloid, Acute 488Melanoma 453Colorectal Neoplasms 446Multiple Myeloma 440Lung Neoplasms 419Pancreatic Neoplasms 352Recurrence 350Lymphoma 349Ovarian Neoplasms 341Lymphoma, Non-Hodgkin 327Leukemia 323Leukemia, Lymphocytic, Chronic, B-Cell 301Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Carcinoma, Renal Cell 256Head and Neck Neoplasms 246Brain Neoplasms 243Carcinoma, Hepatocellular 234Squamous Cell Carcinoma of Head and Neck 231Glioblastoma 231Myelodysplastic Syndromes 229Lymphoma, Large B-Cell, Diffuse 228Lymphoma, Follicular 219Colonic Neoplasms 191Stomach Neoplasms 182Rectal Neoplasms 175

Interventions

lenvatinib 1Pemetrexed 1Docetaxel 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × Advanced Non-small Cell Lung Cancer × Clear all
NCT05001724 2023-04-25

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2/3 Terminated
16 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT02200354 2019-08-14

The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab

Kobe City General Hospital

Phase 2 Terminated
20 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡